Major Challenges Facing Immunotherapy Developers

  

Dr. Marc Better, Vice President of Product Sciences, Kite Pharma - a Keynote Speaker at this years Cell Therapy Bioprocessing & Commercialization Event, sat down to discuss the current projects he is working on at Kite Pharma, the biggest challenges facing immunotherapy developers, regulatory hurdles, and this years meeting. Below you will find a brief teaser from the interview, to access the full interview, follow the links below...

Podcast | Transcript

What are the biggest challenges facing immunotherapy developers?

Well really, I think the biggest challenge for us is that we are charting new ground. There really isn’t a lot of precedent for bringing this type of product to the market. However, we do know - at least in the early trials we are seeing really exciting results both with our collaborators at the NCI and other institutions. We are building a lot of processes and systems around this to allow us to expand these programs and commercialize products like KTC 19.

Any field that is as innovative and exciting as this is very challenging, but we are very committed to being the best in the area that we can possibly be....[Click here to continue reading] 


Want to hear more from Dr. Better? Join him in Alexandria, VA for Cell Therapy Bioprocessing & Commercialization, September 30 - October 2, 2015 - where Dr. Better will have a keynote address titled "Overcoming Challenges for Engineered Autologous T-Cell Therapy". To see the complete agenda, click here. And register now with the code XB15188BLOG to save $100 off the current rate.

See you in Alexandria!

Share this article with your social network, just click below to share now!

Share |

Unlock the Key to Advancing Immuno-Oncology

As innovations and discoveries in cancer immunotherapies progress at lightning speed, it is critical to understand the successes and challenges with current immunotherapies to separate the hype from the real opportunities. IBC's Immuno-Oncology event develops tactics for improving the efficacy and response rates with first generation immunotherapies and builds a strategy for utilizing combination therapies, t-cell therapies, and checkpoint inhibitors to propel the next wave of cancer immunotherapies.

Download the Immuno-Oncology brochure now to create your pathway for an answer to cancer: http://bit.ly/1O6tbIZ

Immuno-Oncology

Advancing the Next Generation of Cancer Immunotherapies

September 30 – October 1, 2015

Hilton Alexandria Mark Center, Alexandria, VA

Register today and explore the latest advances in Immuno-Oncology to:

Develop next generation immunotherapies by understanding recent advances made with CAR-T and T-Cell therapies, checkpoint inhibitors, cancer vaccines, and agnostic antibodies

Create a successful combination therapy strategy by gaining insights from global leaders on effective combinations

Optimize the discovery and development of your promising immunotherapies by hearing best practices and lessons learned from the first wave of cancer immunotherapies

Download the brochure for full program details: http://bit.ly/1O6tbIZ

Reserve your seat now. Use code IMMUNO15BL to get $100 off the current rate. Register today: http://bit.ly/1O6tbIZ

Best,

The Immuno-Oncology Team 2015

@ibcusa

#Immuno15

Related articles

• New Drug Combination Boosts Immune System and Manipulates Gene Activity To Slow Leukemia
• Researchers develop method to increase T cells in melanoma patients

Share this article with your social network, just click below to share now!

Share |